Abstract
Rhodiola rosea, an adaptogen plant from cold regions, has been previously proposed for alleviating dementia and other neurodegenerative diseases. The goal of our study was to evaluate if our proprietary extract (RhodioLife) was able to elicit biological responses related to neuroprotection in neuronal cultures. NS20Y cells were cultured according to procedures and increasing concentrations of RhodioLife were added to the media. Viability at 24h using Presto Blue TM showed no statistically significant differences at those concentrations (0-50 ppm). Quantitative real-time RT-PCR analysis (G-coupled protein receptor [GCPR] array) showed statistically significant (p<0.05) upregulation of 3 genes: calcitonin receptor-like (CALCRL), cyclin-dependent kinase inhibitor 1A (CDKN1A), and lysophosphatidic acid receptor 2 (LPAR2) (4, 3 and 2-fold respectively). In silico evaluation of the bioactives contained in RhodioLife ( www.molinspiration.com ) revealed that Salidroside, Rosarin, Rosavin, Rosiridin, Cinnamyl alcohol and p-Tyrosol all had 1 or no violations of the Lipinski´s rule of five, suggesting favorable pharmacokinetics. The predicted G-coupled protein receptor bioactivity was greatest for Rosarin (0.39) and Salidroside (0.35). We conclude that RhodioLife contained substances which had relevant biological activity and molecular properties suggesting a role in neuroprotection. Studies in suitable animal models are recommended.
Highlights
As the world population grows older and lifespan increases the prevalence of dementia and other neurodegenerative disorders increases
In silico evaluation of the bioactives contained in RhodioLife revealed that Salidroside, Rosarin, Rosavin, Rosiridin, Cinnamyl alcohol and p-Tyrosol all had 1 or no violations of the Lipinskis rule of five, suggesting favorable pharmacokinetics
The predicted G-coupled protein receptor bioactivity was greatest for Rosarin (0.39) and Salidroside (0.35)
Summary
As the world population grows older and lifespan increases the prevalence of dementia and other neurodegenerative disorders increases. More than 24.2 million people worldwide were estimated to have dementia by 2005 and 4.6 millions of new cases have been diagnosed every year since. Prevalence is highest in North America and Western Europe, developing countries are not free of the disease either. The overall prevalence in Africa has been reported to reach 2.4% of those older than 50. Both westernized societies and developing countries share the common traits of increasing prevalence with increasing age (George et al, 2012; Reitz et al 2011). Similar overall estimated costs have been published in Europe (Luengo-Fernández et al, 2011). Until new effective therapies are brought into the regular clinical care preventive interventions, including nutrition are of the utmost importance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
